In vivo CAR-T cell therapy and its technologies: A perspective
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: CAR-T cell therapy research · Virus-based gene therapy research · Biomedical Ethics and Regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (10)
Show source-provided references
1. June C H, O’Connor R S, Kawalekar O U, et al. CAR T cell immunotherapy for human cancer. Science, 2018, 359: 1361–136510.1126/science.aar6711 ↗
2. Li Y R, Zhu Y, Halladay T, et al. In vivo CAR engineering for immunotherapy. Nat Rev Immunol, 2025, 25: 725–74410.1038/s41577-025-01174-1 ↗
3. Short L, Holt R A, Cullis P R, et al. Direct in vivo CAR T cell engineering. Trends Pharmacol Sci, 2024, 45: 406–41810.1016/j.tips.2024.03.004 ↗
4. Milone M C, O’Doherty U. Clinical use of lentiviral vectors. Leukemia, 2018, 32: 1529–154110.1038/s41375-018-0106-0 ↗
5. Nawaz W, Huang B, Xu S, et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J, 2021, 11: 11910.1038/s41408-021-00508-1 ↗
6. Kheirolomoom A, Kare A J, Ingham E S, et al. In situ T-cell transfection by anti- CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials, 2022, 281: 12133910.1016/j.biomaterials.2021.121339 ↗
7. Smith T T, Stephan S B, Moffett H F, et al. In situ programming of leukaemia- specific T cells using synthetic DNA nanocarriers. Nat Nanotech, 2017, 12: 813–82010.1038/nnano.2017.57 ↗
8. Hamilton J R, Chen E, Perez B S, et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol, 2024, 42: 1684–169210.1038/s41587-023-02085-z ↗
9. Zhao G, Zhang Y, Xu C F, et al. In vivo production of CAR-T cells using virus- mimetic fusogenic nanovesicles. Sci Bull, 2024, 69: 354–36610.1016/j.scib.2023.11.055 ↗
10. Elsallab M, Maus M V. Expanding access to CAR T cell therapies through local manufacturing. Nat Biotechnol, 2023, 41: 1698–170810.1038/s41587-023-01981-8 ↗